Chemotherapy and tumour-removal surgery do not address root causes; the body will reactivate its 'defensive plan' elsewhere, so these treatments should be avoided.
Original statement
حذّر الدكتور ضياء العوضي من العلاج الكيميائي والجراحة لإزالة الأورام، معتبراً أنها لا تعالج الأسباب الجذرية، وأن الجسم سيعيد تفعيل خطته الدفاعية في مكان آخر، ورأى أن الخلايا السرطانية تقاوم العلاج الكيماوي بسبب بيئتها الخلالية المتليفة.
not verbatim – paraphrase. Translation by the project; the Arabic wording is authoritative.
Translation
Chemotherapy and tumour-removal surgery do not address root causes; the body will reactivate its 'defensive plan' elsewhere, so these treatments should be avoided.
Origin
- Source status
- Archive quote (no location given)
- Attribution
- Elawady (archive paraphrase; source video not given)
- Origin
- https://eltayebat.com/rule/chemo-radiation/
- Attribution uncertainty
- The archive attributes this text to Dr. Diaa in its 'د. ضياء يقول' box but gives no video reference. Transcript check (the project's research files, keyword search of 307 archive transcripts): found_close_paraphrase. All elements (cancer as a 'defensive plan', no guarantee that cancer will not reappear elsewhere after removal, criticism of tumour surgery) are found across different videos (E3fDJyXYP7E, Ji4i5VHNAZs, dE6jAyxQlJg, plus the existing alt sources); no single passage contains the whole quote.
- Claimed mechanism
Cancer as the body's defensive plan
- Claimed health effect
Treatment futile
- Population concerned
Cancer patients
- Geographic restriction by Elawady
none found
Diverging source versions
ما بتموتش اطلع السرطان دلوقتي يحميك برده
- Source status
- Video transcript (own words)
- Attribution
- Elawady (machine transcript)
- Video
- حاله من وعي وحصار الأصحاء لجهل الاطباء (Open source)
- Published
- 25 March 2026
- Timestamp
- 0:26:11 (location in the original video’s automatic YouTube caption track; confirms where the words occur, not who speaks)
ما ينفعش يا باشا تعالج خلايا خلايا ذاتيه
- Source status
- Video transcript (own words)
- Attribution
- Elawady (machine transcript)
- Video
- Dr.D Clinics - Diaa Al Awady is live! مصير الهيموجلوبين (Open source)
- Published
- 13 May 2025
- Timestamp
- 0:24:07 (location in the original video’s automatic YouTube caption track; confirms where the words occur, not who speaks)
يخرب بيت اهلك ما هو لازم يقاومه انت الكيماوي بتاعك ده بتدخله عايز توصله كل الانترستيشيام ثاني بتموت الخلايا ثاني فالسرطان يبقى اجريسيف اكتر ويطلع في اماكن انت ما بتعرف تسيطر عليه ما انت بتخلقهاني بتدي لهماوي في النسيج
Chemotherapy has to reach the whole interstitium and kills cells again, so the cancer becomes more aggressive and appears in places that cannot be controlled.
- Source status
- Video transcript (own words)
- Attribution
- Elawady (machine transcript)
- Video
- Dr.D Clinics - Diaa Al Awady is live! الغذاء المغشوش (Open source)
- Published
- 31 May 2025
- Timestamp
- 0:26:28 (location in the original video’s automatic YouTube caption track; confirms where the words occur, not who speaks)
- Attribution uncertainty
- Archive transcript (YouTube CC or AI-generated); no timestamps; 'published' is the date listed by the archive and may be the upload date. Live-stream transcripts can contain viewer comments read aloud; the quoted passage was checked in context to be spoken by Elawady.
عايز اقوله من شويه السرطان خطه دفاعيه بتحصل في وقت من الاوقات مقدر ليك تحصل عند سن 600 سنه انت مقدره ليك انا
I wanted to tell him earlier: cancer is a defensive plan that happens at a certain time; it is destined for you ('at age 600' as transcribed, probably a recognition error).
- Source status
- Video transcript (own words)
- Attribution
- Elawady (machine transcript)
- Video
- Dr.D Clinics - Diaa Al Awady is live!التكميم (Open source)
- Published
- 6 May 2025
- Timestamp
- 1:21:45 (location in the original video’s automatic YouTube caption track; confirms where the words occur, not who speaks)
- Attribution uncertainty
- Archive transcript (YouTube CC or AI-generated); no timestamps; YouTube original not checked; wording may contain recognition errors. Matches the 'defensive plan' part of the archive quote.
ما هو دلوقتي السرطان جه ها في الغده وشلت الغده طب انا عندي جرانتي ان ما يجيش سرطان تاني في حته تانيه ما كانش جالك اولاني
Now cancer appeared in the gland and you removed the gland; do I have a guarantee that another cancer will not appear somewhere else?
- Source status
- Video transcript (own words)
- Attribution
- Elawady (machine transcript)
- Video
- الجزء التالت من الندوة (Open source)
- Published
- 2 March 2024
- Timestamp
- 0:02:29 (location in the original video’s automatic YouTube caption track; confirms where the words occur, not who speaks)
- Attribution uncertainty
- Archive transcript (YouTube CC or AI-generated); no timestamps; YouTube original not checked; wording may contain recognition errors. Matches the 'reappears elsewhere after removal' part.
عليا بقى بتوع جراحه الاورام جراحه الاورام ده يا عيني ما يفهمش يعني ايه اورام هو بيخش يشيل الورم هو مالوش دعوه بيه وبي بينقي الليمف نودز بينقي الغدد
Then the tumour surgeons: the tumour surgeon, poor thing, does not understand what tumours are; he goes in to remove the tumour, which is none of his business, and clears out the lymph nodes and glands.
- Source status
- Video transcript (own words)
- Attribution
- Elawady (machine transcript)
- Video
- Dr Diaa Al Awady د ضياء العوضي is live! السيليوليت (Open source)
- Published
- 11 October 2025
- Timestamp
- 0:05:12 (location in the original video’s automatic YouTube caption track; confirms where the words occur, not who speaks)
- Attribution uncertainty
- Archive transcript (YouTube CC or AI-generated); no timestamps; YouTube original not checked; wording may contain recognition errors. Matches the criticism of tumour-removal surgery.
Scientific assessment
False – The statement contradicts the robust evidence.
Certainty of evidence: high – Further research is very unlikely to change the assessment.
1. What was claimed?
Surgery/chemotherapy are futile because cancer is a defensive plan that will reappear elsewhere.
2. What is demonstrably correct?
Treatment does not remove all risk factors (e.g., continued smoking), and some cancers recur despite treatment; recurrence comes from residual or micrometastatic disease.
3. What is wrong or exaggerated?
Recurrence is not an inevitable 'reactivation'. Radiotherapy after breast-conserving surgery reduced 10-year recurrence from 35.0% to 19.3% (I-CHM-02); chemotherapy reduces breast-cancer mortality by about one-third (I-CHM-01); delays of four weeks raise mortality (I-CHM-07); alternative-only care had HR 2.50 for death (I-CHM-03).
4. What remains unclear?
There is a kernel of truth in the related transcript statement that chemotherapy can make cancer more aggressive: in mouse models and in residual human breast tumours after neoadjuvant chemotherapy, chemotherapy increased markers of cancer-cell dissemination (TMEM) and promoted metastasis in mice (I-INTB-04). This is a preclinical and surrogate-marker finding; it does not outweigh the reduction in breast-cancer mortality shown in randomised trials (I-CHM-01).
5. Which studies support it?
Elawady's videos express the same idea (see alt_sources).
6. Which studies contradict it?
I-CHM-01, I-CHM-02, I-CHM-03, I-CHM-07; I-CHM-120 (adjuvant gemcitabine vs observation: 5-year survival 20.7% vs 10.4%); I-CHM-102 (postmastectomy radiotherapy reduced overall recurrence and breast-cancer death); I-CHM-101. Mixed: I-INTB-04 (mouse dissemination markers, no human outcome data).
7. What applies to Germany and Europe?
Standard care is surgery plus risk-adapted adjuvant therapy.
8. What is known about Egypt?
Same.
9. What practical conclusion is appropriate?
Do not refuse or delay indicated surgery or systemic treatment.
Assessment details
- Rationale for certainty of evidence
Randomised evidence shows adjuvant chemotherapy and radiotherapy reduce recurrence and death; replacing or delaying treatment is associated with higher mortality.
- Source quality
Archive paraphrase; consistent with transcripts.
- Regional transferability
High.
- Regional scope of the claim
- general (biological/medical)
- Last reviewed
- 26 October 2026 provisional
Scientific evidence in detail
Scientifically refuted – High-quality evidence shows the opposite, or the claim contradicts well-established physiology.
Research question: Do chemotherapy and tumour surgery fail to address cancer because 'the body reactivates its defensive plan elsewhere', i.e. do they fail to reduce distant recurrence and death?
Research question in detail (PICO)
- Population
- Patients with operable/curable cancers
- Intervention or exposure
- Surgery with or without adjuvant chemotherapy/radiotherapy
- Comparison
- Surgery alone, observation, or no/alternative treatment
- Geographic scope
- universal clinical evidence
- Outcomes
- Distant recurrence
- Overall survival
Study results as reported by the authors. Our assessment follows below.
What speaks for the claim?
Chemotherapy can activate tumour 'exit doors' in mice
Karagiannis GS et al.. Sci Transl Med 2017 · PMID 28679654 · DOI 10.1126/scitranslmed.aan0026 Animal studyfull text, structured risk-of-bias assessmentIn mice, neoadjuvant chemotherapy increased markers of tumour-cell dissemination; in 20 patients, a dissemination-related marker rose after chemotherapy.
- Actual result
- TMEM score increased; no clinical outcome data
- Methodological quality
- low (animal + small human biomarker study)
- Relevance
- very indirect
- Limitations
- No metastasis or survival outcomes in humans
What speaks against the claim?
Chemotherapy after pancreatic cancer surgery
Oettle H et al.. JAMA 2013 · PMID 24104372 · DOI 10.1001/jama.2013.279201 Randomised controlled trialabstract checkednewly addedAfter complete pancreatic cancer surgery, chemotherapy halved early recurrence and doubled 5-year survival compared with observation.
- Actual result
- DFS HR 0.55; 5-y OS 20.7% vs 10.4%
- Methodological quality
- high (RCT, 136-month follow-up)
- Relevance
- direct
- Limitations
- Open-label
Radiotherapy after breast removal: 20-year results of 22 trials
EBCTCG; McGale P et al.. Lancet 2014 · PMID 24656685 · DOI 10.1016/S0140-6736(14)60488-8 Meta-analysisfull text checkednewly addedRadiotherapy after mastectomy reduced overall recurrence (including distant) and breast-cancer death in node-positive women.
- Actual result
- 10-y recurrence 62.5% -> 51.9%; 20-y BC mortality 66.4% -> 58.3%
- Methodological quality
- high (IPD meta-analysis)
- Relevance
- direct
- Limitations
- Old techniques
Chemotherapy after breast-cancer surgery reduces deaths by about a third
EBCTCG. Lancet 2012 · PMID 22152853 · DOI 10.1016/S0140-6736(11)61625-5 Meta-analysisfull text, structured risk-of-bias assessmentChemotherapy versus none reduced breast-cancer mortality and overall mortality.
- Actual result
- Any anthracycline regimen vs none: breast cancer mortality RR 0.79
- Methodological quality
- high (IPD meta-analysis)
- Relevance
- direct
- Limitations
- None material
What does the overall evidence say?
Editorial assessment based on the studies above – not itself a study result.
Which position is better supported?
Adjuvant chemotherapy and radiotherapy after surgery reduce distant recurrence and death; there is no evidence of a 'reactivation elsewhere' that cancels the benefit.
Why some studies weigh more
Randomised trials with distant recurrence and survival outcomes are decisive; a mouse dissemination signal cannot outweigh human survival data.
Is a causal relationship established? Yes, established Randomised comparisons.
Remaining uncertainty
Treatment-induced dissemination signals (I-INTB-04) deserve research but are not reflected in human outcomes.
Justified conclusion
False.
Why do studies seem to disagree?
I-INTB-04 (dissemination markers after chemotherapy in mice) versus randomised trials (fewer distant recurrences): the biomarker signal is real in models but the net clinical effect in humans is fewer metastases and deaths.
Does this depend on the country?
- General biological effects
- Universal clinical evidence.
- Eating habits
- Not relevant.
- Origin of the food
- Not relevant.
- Contaminants
- Not relevant.
- National production conditions
- Not relevant.
- Legal rules
- Not relevant.
- Actual monitoring data
- No monitoring data relevant.
A regional difference that changes the conclusion is not supported by robust data.
Statistical re-check
- NNT – NNT about 10 for one extra 5-year survivor; HR 0.76 (0.61-0.95) log-symmetric recalculated
- Log-symmetry – HR 2.50 (1.88-3.27) symmetric on log scale recalculated
Certainty of the overall evidence (GRADE, simplified)
- Main outcome
- Distant recurrence and survival with adjuvant therapy
- Starting level
- high (randomised trials)
- Result
- high
Simplified assessment by a single reviewer, following the GRADE approach; not a formal GRADE panel. GRADE rates the body of evidence for one outcome, not individual studies.
Clinical guidelines and official statements checked
- NICE: Early and locally advanced breast cancer: diagnosis and management (NG101) (2018, last updated 14 April 2025) · Original publication
Offer whole-breast radiotherapy after breast-conserving surgery with clear margins; offer postmastectomy radiotherapy for node-positive disease or involved margins; do not offer postmastectomy radiotherapy to people at low risk of local recurrence; where adjuvant chemotherapy is indicated, offer a regimen containing a taxane and an anthracycline and discuss benefits and risks. - WHO: Cancer - fact sheet (2026 (page fetched 2026-10-26)) · Original publication
Many cancers can be cured if detected early and treated effectively; treatment usually includes surgery, radiotherapy and/or systemic therapy; some cancers such as testicular seminoma and childhood leukaemias and lymphomas have high cure rates with appropriate treatment even when spread; palliative care relieves symptoms in advanced cancer.
Search strategy
Documented literature searches for this review (search strings in the original database syntax).
| Database | Date | Search | Looking for | Hits | Included |
|---|---|---|---|---|---|
| Europe PMC | 26 October 2026 | (TITLE:"refusal" OR TITLE:"refuse" OR TITLE:"declined" OR TITLE:"decline") AND (TITLE:"chemotherapy" OR TITLE:"radiotherapy" OR TITLE:"radiation" OR TITLE:"conventional") AND TITLE:"survival" AND PUB_YEAR:[2015 TO 2026] | both directions | 15 | |
| PubMed | 26 October 2026 | (chemotherapy[ti] OR radiotherapy[ti]) AND (refus*[ti] OR declin*[ti] OR omission[ti]) AND (survival[ti] OR mortality[ti]) AND 2015:2026[dp] | both directions | 11 | |
| Europe PMC | 26 October 2026 | TITLE:"Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer" | contradicting evidence | 1 | |
| PubMed | 26 October 2026 | "Early Breast Cancer Trialists Collaborative Group"[Corporate Author] AND Lancet[ta] AND 2012:2026[dp] | contradicting evidence | 12 | |
| Europe PMC | 26 October 2026 | (TITLE:"chemotherapy" OR TITLE:"cancer treatment") AND (TITLE:"more harm than good" OR TITLE:"overtreatment" OR TITLE:"futile" OR TITLE:"no survival benefit") AND PUB_YEAR:[2010 TO 2026] | supporting evidence | 253 |
Open questions
None material for the verdict.
How deeply was this checked?
8 linked studies: 6 checked in full text (4 of them with a structured risk-of-bias assessment), 2 on the basis of the abstract, 0 bibliographically only. No formal assessment with two independent reviewers and no independent human expert review has taken place yet.
Last scientific review: 26 October 2026
History of the verdict
- 25 October 2026 · Phase 1 · Initial assessment: False (high)
- 26 October 2026 · Phase 4 (systematic evidence review) · Re-examined with extended evidence; verdict unchanged: False (high)
New randomised evidence (pancreatic and breast cancer) confirms the conclusion.
New sources: I-CHM-101 I-CHM-102 I-CHM-120
In plain language
The archive says Dr. Diaa warned against chemotherapy and surgery because the body would just make the tumour again elsewhere. Large studies show the opposite: after surgery, radiotherapy halves the chance of recurrence and chemotherapy lowers the chance of dying by about a third. People who refuse or delay these treatments die more often.
Studies on this claim
Studies supporting the claim (0)
No studies in this group.
Studies contradicting or limiting the claim (7)
-
Chemotherapy after breast-cancer surgery reduces deaths by about a third
EBCTCG. Lancet 2012 · PMID 22152853 · DOI 10.1016/S0140-6736(11)61625-5Meta-analysisindependent cross-checkfull text, structured risk-of-bias assessment★ key studyIn 123 trials with 100,000 women, modern regimens cut breast-cancer deaths by about one-third, and overall deaths fell too.
Adjuvant therapy prevents recurrence/death
Does the study support the specific claim? No · Methodological quality: high · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Compare chemotherapy regimens and no chemotherapy.
- How was the study done?
IPD meta-analysis of RCTs.
- How many people, animals or samples were studied?
~100,000 women.
- What was actually found?
~1/3 lower breast-cancer mortality.
- How large was the observed effect?
RR 0.64-0.78 vs none.
- What do the results mean in everyday life?
For many women, chemotherapy substantially raises the chance of survival.
- What are the study's limitations?
Trials versus no chemotherapy are old (median start 1986); a small excess of non-breast-cancer deaths (e.g. heart, leukaemia) occurred; benefit is small when baseline risk is low.
- What does it say about Elawady's specific claim?
Contradicts claims that chemotherapy is useless.
- Do the results apply to Germany and Europe?
High.
- What can explicitly not be concluded from this study?
Individual benefit without risk assessment.
-
Radiotherapy after breast-conserving surgery halves recurrence
EBCTCG. Lancet 2011 · PMID 22019144 · DOI 10.1016/S0140-6736(11)61629-2Meta-analysisindependent cross-checkfull text, structured risk-of-bias assessment★ key studyRecurrence within 10 years fell from 35% to 19%, and breast-cancer deaths within 15 years from 25% to 21%.
Recurrence halved
Does the study support the specific claim? No · Methodological quality: high · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Measure radiotherapy benefit.
- How was the study done?
IPD meta-analysis.
- How many people, animals or samples were studied?
10,801 women.
- What was actually found?
Recurrence halved; breast-cancer deaths about one-sixth lower; deaths from any cause at 15 years 3.0 percentage points lower.
- How large was the observed effect?
-15.7% recurrence; -3.8% death.
- What do the results mean in everyday life?
Radiotherapy markedly lowers the chance the cancer returns.
- What are the study's limitations?
Older techniques; risk groups derived from the same data; in low-risk node-negative women the gain in survival was small and uncertain.
- What does it say about Elawady's specific claim?
Benefit side.
- Do the results apply to Germany and Europe?
High.
- What can explicitly not be concluded from this study?
Individual benefit size without risk factors.
-
Patients who used only alternative medicine for curable cancer died more often
Johnson SB et al.. J Natl Cancer Inst 2018 · PMID 28922780 · DOI 10.1093/jnci/djx145Cohort studyindependent cross-checkabstract checked★ key studyRisk of death was 2.5 times higher overall and 5.7 times higher for breast cancer.
Treatment matters for survival
Does the study support the specific claim? No · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Compare AM-only vs conventional treatment.
- How was the study done?
Matched registry cohort.
- How many people, animals or samples were studied?
840 matched patients.
- What was actually found?
HR 2.50 for death.
- How large was the observed effect?
HR 5.68 breast cancer.
- What do the results mean in everyday life?
Replacing cancer treatment with alternatives is dangerous.
- What are the study's limitations?
Observational.
- What does it say about Elawady's specific claim?
Contradicts refusing therapy.
- Do the results apply to Germany and Europe?
Moderate.
- What can explicitly not be concluded from this study?
Effects of complementary approaches used alongside treatment.
-
Each month of delay in cancer treatment raises the risk of death
Hanna TP et al.. BMJ 2020 · PMID 33148535 · DOI 10.1136/bmj.m4087Meta-analysisindependent cross-checkfull text, structured risk-of-bias assessment★ key studyFor example, every 4-week delay of breast surgery was linked to 8% higher mortality.
Timely treatment matters
Does the study support the specific claim? No · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Quantify harm from delay.
- How was the study done?
Meta-analysis.
- How many people, animals or samples were studied?
1.27 million patients.
- What was actually found?
Higher mortality with delay.
- How large was the observed effect?
HR 1.06-1.08 per 4 weeks (surgery).
- What do the results mean in everyday life?
Do not postpone recommended treatment.
- What are the study's limitations?
Observational, mostly US registry data; valid only for delays of about 4-16 weeks; not suitable for predicting an individual's risk.
- What does it say about Elawady's specific claim?
Safety.
- Do the results apply to Germany and Europe?
High.
- What can explicitly not be concluded from this study?
The effect of delays longer than 16 weeks or of refusing treatment altogether; the effect for every cancer type; proof of causation.
-
Chemotherapy for early breast cancer: benefits and risks in 100,000 women
Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Lancet 2023 · PMID 37061269 · DOI 10.1016/S0140-6736(23)00285-4Meta-analysisindependent cross-checkfull text checked★ key studyAnthracycline-taxane chemotherapy lowered recurrence and breast-cancer death; it caused about one extra leukaemia per 700 women and no measurable excess heart deaths within about 5 years.
Chemotherapy reduces distant recurrence and breast-cancer death; no 'reactivation elsewhere' effect.
Does the study support the specific claim? Partly · Methodological quality: high · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Weigh benefits and risks of anthracycline-containing chemotherapy
- How was the study done?
Pooled individual data from randomised trials
- How many people, animals or samples were studied?
18,103 women in the main comparison; about 100,000 overall
- What was actually found?
Fewer recurrences (RR 0.86) and fewer breast-cancer deaths; AML 0.18% vs 0.03%
- How large was the observed effect?
10-year recurrence 16.4% vs 18.9%; up to 8.7 points fewer recurrences with concurrent anthracycline
- What do the results mean in everyday life?
For every leukaemia caused, roughly 18 recurrences are prevented in this data set
- What are the study's limitations?
Short follow-up for heart effects; high-risk heart patients often excluded
- What does it say about Elawady's specific claim?
Harms of chemotherapy are real (AML) but small compared with the benefit; this contradicts the idea that harms outweigh benefits
- Do the results apply to Germany and Europe?
High
- What can explicitly not be concluded from this study?
Cannot quantify heart failure 15-20 years after treatment
-
Radiotherapy after breast removal: 20-year results of 22 trials
EBCTCG; McGale P et al.. Lancet 2014 · PMID 24656685 · DOI 10.1016/S0140-6736(14)60488-8Meta-analysisindependent cross-checkfull text checked★ key studyIn women with cancer in the lymph nodes, radiotherapy prevented about 1 in 10 recurrences and about 1 in 12 breast-cancer deaths; in low-risk women with old techniques it did more harm than good.
Local treatment also reduced distant recurrence and death, contrary to 'the body will recreate the tumour elsewhere'.
Does the study support the specific claim? No · Methodological quality: high · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Test whether radiotherapy after mastectomy saves lives
- How was the study done?
Pooled individual data from 22 randomised trials
- How many people, animals or samples were studied?
8135 women, 1964-86
- What was actually found?
Benefit in node-positive disease; overall mortality increase in node-negative women after full axillary surgery
- How large was the observed effect?
pN+: recurrence 62.5% -> 51.9%; breast-cancer death 66.4% -> 58.3%
- What do the results mean in everyday life?
Radiotherapy helps when recurrence risk is substantial and can harm when it is low
- What are the study's limitations?
Old techniques; modern doses are lower
- What does it say about Elawady's specific claim?
Contradicts blanket claims that radiotherapy does more harm than good; supports careful selection
- Do the results apply to Germany and Europe?
Moderate to high
- What can explicitly not be concluded from this study?
Cannot give exact absolute benefits for today's patients
-
Chemotherapy after pancreatic cancer surgery
Oettle H et al.. JAMA 2013 · PMID 24104372 · DOI 10.1001/jama.2013.279201Randomised controlled trialindependent cross-checkabstract checked★ key studyChemotherapy after surgery doubled 5-year survival (21% vs 10%) compared with surgery alone.
Surgery plus chemotherapy reduced recurrence and doubled 5-year survival vs surgery alone.
Does the study support the specific claim? No · Methodological quality: high · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Test chemotherapy after pancreatic surgery
- How was the study done?
Randomised trial
- How many people, animals or samples were studied?
354 patients
- What was actually found?
Longer survival with chemotherapy
- How large was the observed effect?
5-y OS 20.7% vs 10.4%
- What do the results mean in everyday life?
Even in a hard-to-treat cancer, chemotherapy saves some lives
- What are the study's limitations?
Open-label
- What does it say about Elawady's specific claim?
Contradicts 'chemo cannot work because of fibrosis'
- Do the results apply to Germany and Europe?
High
- What can explicitly not be concluded from this study?
Cannot promise cure for an individual
No study in this group is marked as key.
Studies with mixed or unclear results (1)
-
Chemotherapy can activate tumour 'exit doors' in mice
Karagiannis GS et al.. Sci Transl Med 2017 · PMID 28679654 · DOI 10.1126/scitranslmed.aan0026Animal studyindependent cross-checkfull text, structured risk-of-bias assessmentIn mice and in residual human tumours, chemotherapy increased markers of cancer-cell dissemination.
Kernel for pro-metastatic effects; does not outweigh survival benefit.
Does the study support the specific claim? Partly · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Test whether chemotherapy promotes metastasis
- How was the study done?
Mouse models and human residual tumour tissue
- How many people, animals or samples were studied?
Mice (about 11 per group) and 20 patients with residual tumour after chemotherapy
- What was actually found?
More TMEM activity and metastasis in mice; higher TMEM scores in humans
- How large was the observed effect?
2-3-fold higher TMEM score and about 2-fold more circulating tumour cells in mice; TMEM score increased in all 20 patients (no outcome data)
- What do the results mean in everyday life?
Chemotherapy can have unwanted biological effects, which researchers try to block with added drugs.
- What are the study's limitations?
Mainly mice; human part small, selected and without outcome data; authors hold a related patent
- What does it say about Elawady's specific claim?
Partly supports 'chemo makes cancer more aggressive' as a biological possibility; does not show worse survival.
- Do the results apply to Germany and Europe?
Moderate
- What can explicitly not be concluded from this study?
Cannot conclude that chemotherapy shortens life or should be avoided.
No study in this group is marked as key.
Regional context
Germany / EU
Standard care is surgery plus risk-adapted adjuvant therapy.
Egypt
Same.
What applies in my country?
General scientific assessment
False This claim is false: randomised trials show that surgery combined with chemotherapy or radiotherapy reduces distant recurrence and death (for example, chemotherapy after pancreatic cancer surgery doubled 5-year survival, I-CHM-120); there is no evidence that the body 'reactivates' the cancer elsewhere because of treatment.
This statement concerns biological or medical relationships. The scientific assessment above applies regardless of the country; country-specific food data do not change it.
References
- Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials.. EBCTCG. Lancet 2012 · PMID 22152853 · DOI 10.1016/S0140-6736(11)61625-5
- Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials.. EBCTCG. Lancet 2011 · PMID 22019144 · DOI 10.1016/S0140-6736(11)61629-2
- Use of Alternative Medicine for Cancer and Its Impact on Survival.. Johnson SB et al.. J Natl Cancer Inst 2018 · PMID 28922780 · DOI 10.1093/jnci/djx145
- Mortality due to cancer treatment delay: systematic review and meta-analysis.. Hanna TP et al.. BMJ 2020 · PMID 33148535 · DOI 10.1136/bmj.m4087
- Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of 100 000 women from 86 randomised trials.. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Lancet 2023 · PMID 37061269 · DOI 10.1016/S0140-6736(23)00285-4
- Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials.. EBCTCG; McGale P et al.. Lancet 2014 · PMID 24656685 · DOI 10.1016/S0140-6736(14)60488-8
- Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial.. Oettle H et al.. JAMA 2013 · PMID 24104372 · DOI 10.1001/jama.2013.279201
- Neoadjuvant chemotherapy induces breast cancer metastasis through a TMEM-mediated mechanism.. Karagiannis GS et al.. Sci Transl Med 2017 · PMID 28679654 · DOI 10.1126/scitranslmed.aan0026